122536-74-7

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-N-CBZ-3-N-BOC-AMINO PYRROLIDINE is used as a building block for the synthesis of various peptidomimetic compounds and potential drug candidates. Its unique chemical reactivity and functional groups make it a key starting material for the preparation of biologically active compounds.
Used in Chiral Pharmaceutical Production:
(S)-1-N-CBZ-3-N-BOC-AMINO PYRROLIDINE is used as a chiral intermediate for the production of chiral pharmaceuticals and agrochemicals, leveraging its chiral nature to create enantiomerically pure compounds, which are essential for the development of effective and safe medications.
Used in Drug Discovery and Development:
(S)-1-N-CBZ-3-N-BOC-AMINO PYRROLIDINE is utilized as a key molecule in drug discovery and development due to its potential antiviral and antifungal properties. Its study and application contribute to the advancement of new therapeutic agents against various diseases and conditions.

Upstream product

• 501-53-1 benzyl chloroformate 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 122536-72-5 (S)-3-amino-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 122536-68-9 (R)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 122536-70-3 (S)-3-azido-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 100858-33-1 (3R)-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester 

Downstream Products

• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 1412255-43-6 tert-butyl (S)-1-((R)-1-(6-chloropyridin-3-yl)-2,2,2-trifluoroethyl)pyrrolidin-3-yl(2-fluoroethyl)carbamate 
• 169750-01-0 (S)-3-[N-(tert-butoxycarbonyl)-N-methylamino]pyrrolidine 
• 1412255-95-8 (S)-benzyl 3-(tert-butoxycarbonyl(2-tert-butoxyethyl)amino)pyrrolidine-1-carboxylate 
• 1412254-93-3 benzyl (3S)-3-[tert-butoxycarbonyl(methyl)amino]pyrrolidine-1-carboxylate 
• 550378-39-7 (S)-benzyl 3-aminopyrrolidine-1-carboxylate hydrochloride 
• 1312756-08-3 (S)-benzyl 3-(tert-butoxycarbonyl(3-fluoropropyl)amino)pyrrolidine-1-carboxylate 
• 122536-72-5 (S)-3-amino-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 1361322-93-1 (S)-benzyl 3-((S)-2-((S)-2-(tert-butoxycarbonyl(methyl)amino)propanamido)-2-cyclohexylacetamido)pyrrolidine-1-carboxylate 
• 1361322-92-0 (S)-benzyl 3-((S)-2-amino-2-cyclohexylacetamido)pyrrolidine-1-carboxylate hydrochloride 
• 1361322-91-9 (S)-benzyl 3-((S)-2-(tert-butoxycarbonylamino)-2-cyclohexylacetamido)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of DS34942424: An orally potent analgesic without mu opioid receptor agonist activity

We identified (5′S)-10′-fluoro-6′-methyl-5′,6′-dihydro-3′H-spiro[cyclopropane-1,4′-[2,6]diaza[2,5]methano[2,6]benzodiazonin]-7′(1′H)-one, 22b (DS34942424) with a unique and original bicyclic skeleton. 22b showed an orally potent analgesic in the acetic ac

Discovery of aminopiperidine-based Smac mimetics as IAP antagonists

A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over XIAP is observed for these compounds, which is attributed to a slight difference in the binding groove between the two proteins and the resulting steric interactions with the inhibitors. XIAP binding can be improved by constraining the inhibitor so that these unfavorable steric interactions are minimized.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER

The invention relates to 1, 7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk 1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Amidoheterocycles as modulators of the melanocortin-4 receptor

Novel azetidinyl and pyrrolidinyl compounds are ligands of melanocortin-4 receptors and are useful for treating conditions responsive to the modulation of melanocortin-4 receptors such as obesity, diabetes, and sexual dysfunction.

Antithrombotic agents

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well a

Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3- amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity

A series of amino acid prodrugs of racemic and chiral 7-(3-amino-1- pyrrolidinyl)-6-fluoro-1,8-naphthyridine-3-carboxylic acids, 1-cyclopropyl- 6,8-difluoro-3-quinolinecarboxylic acids, 1-cyclopropyl-6-fluoro-3- quinolinecarboxylic acids, and 5-amino-1-cyclopropyl-6,8-difluoro-3- quinolinecarboxylic acids have been prepared and evaluated for comparative antibacterial activity. Compounds were prepared by acylation of the 3-amino group of the pyrrolidine with common amino acids using standard peptide chemistry. This series has been compared with the parent compounds for antibacterial activity in vitro and in vivo as well as for comparative solubility. The amino acid analogues were less active in vitro, but had equal or increased efficacy in vivo. Indeed, it was proven that these compounds, which were stable to acid and base under the reaction conditions for their preparation, were rapidly cleaved in serum to give the parent quinolones. The amino acid derivatives showed a 3-70 times improved solubility when compared to the parent compounds. The most active compound of the series was [S- (R*,R*)]-7-[3-[(2-amino-1-oxopropyl)-amino]-1-pyrrolidinyl]-1-cyclopropyl- 6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (PD 131112).